Caveolin 1 modulates aldosterone-mediated pathways of glucose and lipid homeostasis

Journal of the American Heart Association

Volumn 5, Issue 10, 2016, Pages

  Baudrand, Rene ^a,b   Gupta, Nidhi ^a   Garza, Amanda E ^a   Vaidya, Anand ^a   Leopold, Jane A ^a   Hopkins, Paul N ^c   Jeunemaitre, Xavier ^d   Ferri, Claudio ^e   Romero, Jose R ^a   Williams, Jonathan ^a   Loscalzo, Joseph ^a   Adler, Gail K ^a   Williams, Gordon H ^a   Pojoga, Luminita H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Aldosterone; Caveolin 1; Dyslipidemia; Eplerenone; Insulin resistance; Mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; CAVEOLIN 1; CHOLESTEROL; EPLERENONE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RESISTIN; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL; ALDEHYDE REDUCTASE; CAV1 PROTEIN, HUMAN; CAV1 PROTEIN, MOUSE; GLUCOSE; MINERALOCORTICOID ANTAGONIST; NOX4 PROTEIN, MOUSE; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, MOUSE; RETN PROTEIN, MOUSE; SPIRONOLACTONE;

ADULT; ALLELE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CAV1 GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENETIC VARIATION; GENOTYPE; GLUCOSE HOMEOSTASIS; HETEROZYGOSITY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IN VIVO STUDY; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIPID HOMEOSTASIS; MALE; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE GENETICS; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; ADIPOSE TISSUE; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GENE FREQUENCY; GENETICS; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADIPOSE TISSUE; ADOLESCENT; ADULT; AGED; ALDEHYDE REDUCTASE; ALDOSTERONE; ANIMALS; BLOOD GLUCOSE; CAVEOLIN 1; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; GENE FREQUENCY; GLUCOSE; HOMEOSTASIS; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEINS, HDL; LIVER; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NADPH OXIDASE 4; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, MINERALOCORTICOID; RESISTIN; RETINOL-BINDING PROTEINS, PLASMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPIRONOLACTONE; TRIGLYCERIDES; YOUNG ADULT;

EID: 84994444308     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.116.003845     Document Type: Article

References (67)

1. Pimenta E, Gordon RD, Stowasser M. Salt, aldosterone and hypertension. J Hum Hypertens. 2013;27:1-6.
2. Fallo F, Federspil G, Veglio F, Mulatero P. The metabolic syndrome in primary aldosteronism. Curr Diab Rep. 2008;8:42-47.
3. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, Rabbia F, Federspil G, Mulatero P. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454-459.
4. Raheja P, Price A, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Vongpatanasin W. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60:319-325.
5. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253-2261.
6. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res. 2009;84:164-172.
7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
8. Underwood PC, Adler GK. The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep. 2013;15:59-70.
9. Yamashita R, Kikuchi T, Mori Y, Aoki K, Kaburagi Y, Yasuda K, Sekihara H. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J. 2004;51:243-251.
10. Feraco A, Armani A, Mammi C, Fabbri A, Rosano GM, Caprio M. Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity. J Steroid Biochem Mol Biol. 2013;137:99-106.
11. Pojoga LH, Underwood PC, Goodarzi MO, Williams JS, Adler GK, Jeunemaitre X, Hopkins PN, Raby BA, Lasky-Su J, Sun B, Cui J, Guo X, Taylor KD, Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH. Variants of the caveolin-1 gene: a translational investigation linking insulin resistance and hypertension. J Clin Endocrinol Metab. 2011;96:E1288-E1292
12. Baudrand R, Goodarzi MO, Vaidya A, Underwood PC, Williams JS, Jeunemaitre X, Hopkins PN, Brown N, Raby BA, Lasky-Su J, Adler GK, Cui J, Guo X, Taylor KD, Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Pojoga LH. A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. Metabolism. 2015;64:1674-1681.
13. Chuengsamarn S, Garza AE, Krug AW, Romero JR, Adler GK, Williams GH, Pojoga LH. Direct renin inhibition modulates insulin resistance in caveolin-1-deficient mice. Metabolism. 2013;62:275-281.
14. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, Lisanti MP. Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol. 2003;285:C222-C235.
15. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE, Lisanti MP. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem. 2002;277:8635-8647.
16. Gildea JJ, Kemp BA, Howell NL, Van Sciver RE, Carey RM, Felder RA. Inhibition of renal caveolin-1 reduces natriuresis and produces hypertension in sodiumloaded rats. Am J Physiol Renal Physiol. 2011;300:F914-F920.
17. Ricchiuti V, Lapointe N, Pojoga L, Yao T, Tran L, Williams GH, Adler GK. Dietary sodium intake regulates angiotensin II type 1, mineralocorticoid receptor, and associated signaling proteins in heart. J Endocrinol. 2011;211:47-54.
18. Pojoga LH, Yao TM, Sinha S, Ross RL, Lin JC, Raffetto JD, Adler GK, Williams GH, Khalil RA. Effect of dietary sodium on vasoconstriction and eNOSmediated vascular relaxation in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol. 2008;294:H1258-H1265.
19. Pojoga LH, Adamova Z, Kumar A, Stennett AK, Romero JR, Adler GK, Williams GH, Khalil RA. Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol. 2010;298:H1776-H1788.
20. Pojoga LH, Romero JR, Yao TM, Loutraris P, Ricchiuti V, Coutinho P, Guo C, Lapointe N, Stone JR, Adler GK, Williams GH. Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II. Endocrinology. 2010;151:1236-1246.
21. Lee S, Muniyappa R, Yan X, Chen H, Yue LQ, Hong EG, Kim JK, Quon MJ. Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice. Am J Physiol Endocrinol Metab. 2008;294:E261-E270.
22. Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J. 2001;15:1771-1773.
23. Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH, Adler GK. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension. 2013;61:886-893.
24. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, Sekowska M, Travers M, Potter S, Grundberg E, Small K, Hedman AK, Bataille V, Tzenova BELL J, Surdulescu G, Dimas AS, Ingle C, Nestle FO, di Meglio P, Min JL, Wilk A, Hammond CJ, Hassanali N, Yang TP, Montgomery SB, O'Rahilly S, Lindgren CM, Zondervan KT, Soranzo N, Barroso I, Durbin R, Ahmadi K, Deloukas P, McCarthy MI, Dermitzakis ET, Spector TD. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 2011;7: e1002003.
25. Abate N, Sallam HS, Rizzo M, Nikolic D, Obradovic M, Bjelogrlic P, Isenovic ER. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2013;20:4961-4969.
26. Norseen J, Hosooka T, Hammarstedt A, Yore MM, Kant S, Aryal P, Kiernan UA, Phillips DA, Maruyama H, Kraus BJ, Usheva A, Davis RJ, Smith U, Kahn BB. Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinaseand toll-like receptor 4-dependent and retinol-independent mechanism. Mol Cell Biol. 2012;32:2010-2019.
27. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD, Goldstein BJ. The NAD(P)H oxidase homolog Nox4 modulates insulinstimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol Cell Biol. 2004;24:1844-1854.
28. Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y. Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol. 2006;47:609-613.
29. Yasunari K, Kohno M, Kano H, Minami M, Yoshikawa J. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose. Hypertension. 2000;35:1092-1098.
30. Zhang Z, Liew CW, Handy DE, Zhang Y, Leopold JA, Hu J, Guo L, Kulkarni RN, Loscalzo J, Stanton RC. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis. FASEB J. 2010;24:1497-1505.
31. Park J, Rho HK, Kim KH, Choe SS, Lee YS, Kim JB. Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Mol Cell Biol. 2005;25:5146-5157.
32. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13:189-197.
33. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab. 2010;95:1986-1990.
34. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol. 2009;308:53-62.
35. Krug AW, Pojoga LH, Williams GH, Adler GK. Cell membrane-associated mineralocorticoid receptors?Newevidence. Hypertension. 2011;57:1019-1025.
36. Baudrand R, Pojoga LH, Romero JR, Williams GH. Aldosterone"s mechanism of action: roles of lysine-specific demethylase 1, caveolin and striatin. Curr Opin Nephrol Hypertens. 2014;23:32-37.
37. Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, Selhub J, D'Agostino RB Sr, Wang TJ, Vasan RS. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116:984-992.
38. Syed SB, Qureshi MA. Association of aldosterone and cortisol with cardiovascular risk factors in prehypertension stage. Int J Hypertens. 2012;2012:906327.
39. Mineo C, Shaul PW. Regulation of eNOS in caveolae. Adv Exp Med Biol. 2012;729:51-62.
40. Hayashi T, Juliet PA, Miyazaki A, Ignarro LJ, Iguchi A. High glucose downregulates the number of caveolae in monocytes through oxidative stress from NADPH oxidase: implications for atherosclerosis. Biochim Biophys Acta. 2007;1772:364-372.
41. Fruhbeck G, Lopez M, Dieguez C. Role of caveolins in body weight and insulin resistance regulation. Trends Endocrinol Metab. 2007;18:177-182.
42. Asterholm IW, Mundy DI, Weng J, Anderson RG, Scherer PE. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell Metab. 2012;15:171-185.
43. Barker A, Langenberg C, Wareham NJ. Genetic determinants of glucose homeostasis. Best Pract Res Clin Endocrinol Metab. 2012;26:159-170.
44. Liu G, Grifman M, Keily B, Chatterton JE, Staal FW, Li QX. Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production. Biochem Biophys Res Commun. 2006;342:1291-1296.
45. Wada T, Kenmochi H, Miyashita Y, Sasaki M, Ojima M, Sasahara M, Koya D, Tsuneki H, Sasaoka T. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology. 2010;151:2040-2049.
46. Garg R, Adler GK. Role of mineralocorticoid receptor in insulin resistance. Curr Opin Endocrinol Diabetes Obes. 2012;19:168-175.
47. Luo P, Dematteo A, Wang Z, Zhu L, Wang A, Kim HS, Pozzi A, Stafford JM, Luther JM. Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia. 2013;56:901-910.
48. Pojoga LH, Yao TM, Opsasnick LA, Garza AE, Reslan OM, Adler GK, Williams GH, Khalil RA. Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice. J Pharmacol Exp Ther. 2014;348:260-270.
49. Shah AS, Urbina EM, Khoury PR, Kimball TR, Dolan LM. Lipids and lipoprotein ratios: contribution to carotid intima media thickness in adolescents and young adults with type 2 diabetes mellitus. J Clin Lipidol. 2013;7:441-445.
50. Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J Lipid Res. 2009;50(suppl):S178-S182.
51. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006;354:2552-2563.
52. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436:356-362.
53. Gonzalez-Munoz E, Lopez-Iglesias C, Calvo M, Palacin M, Zorzano A, Camps M. Caveolin-1 loss of function accelerates glucose transporter 4 and insulin receptor degradation in 3T3-L1 adipocytes. Endocrinology. 2009;150:3493-3502.
54. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, D'Angelo A, Cicero AF. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res. 2011;34:145-151.
55. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes. 2004;53:1937-1941.
56. Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, De Toma G, Sciomer S, Letizia C. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab. 2010;95:2391-2398.
57. Bocanegra V, Manucha W, Pena MR, Cacciamani V, Valles PG. Caveolin-1 and Hsp70 interaction in microdissected proximal tubules from spontaneously hypertensive rats as an effect of Losartan. J Hypertens. 2010; 28:143-155.
58. Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol. 2012;3:87.
59. Bayorh MA, Rollins-Hairston A, Adiyiah J, Lyn D, Eatman D. Eplerenone suppresses aldosterone/salt-induced expression of NOX-4. J Renin Angiotensin Aldosterone Syst. 2011;12:195-201.
60. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, Qazi M, Morris EM, Cooper SA, Link CD, Stump C, Hay M, Ferrario C, Sowers JR. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology. 2007;148:3773-3780.
61. Ramana KV. ALDOSE REDUCTASE: new insights for an old enzyme. Biomol Concepts. 2011;2:103-114.
62. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res. 2007;101:455-464.
63. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": a transcriptional informatics analysis with validation. Cell Cycle. 2010;9:2201-2219.
64. Ruhs S, Stratz N, Schlor K, Meinel S, Mildenberger S, Rabe S, Gekle M, Grossmann C. Modulation of transcriptional mineralocorticoid receptor activity by nitrosative stress. Free Radic Biol Med. 2012;53:1088-1100.
65. Desjardins F, Lobysheva I, Pelat M, Gallez B, Feron O, Dessy C, Balligand JL. Control of blood pressure variability in caveolin-1-deficient mice: role of nitric oxide identified in vivo through spectral analysis. Cardiovasc Res. 2008;79:527-536.
66. Stanton RC. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life. 2012;64:362-369.
67. Leopold JA, Zhang YY, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide. Arterioscler Thromb Vasc Biol. 2003;23:411-417.